Evidence map›Paper›PMID 36922645›Full record

SynthesisEye (London, England)2023

Frequency of coexistent eye diseases and cognitive impairment or dementia: a systematic review and meta-analysis.

Ying Xu, Jack Phu, Htein Linn Aung, Negin Hesam-Shariati, Lisa Keay, Phillip J Tully, Andrew Booth, Craig S Anderson, Kaarin J Anstey, Ruth Peters

Open access · hybridAbstract readMeta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Eye (London, England), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 3 pooled it
4.5field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 3 syntheses or guidelines pooled it, 16 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Review
  5. Ocular Glymphatic System: Its Modulation and Role in Intraocular Tumors.Investigative ophthalmology & visual science · 2026
    Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Observational
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 4 countries.

Ying XuNeuroscience Research Australia, Sydney, NSW, Australia. y.xu@neura.edu.au.ORCID 0000-0002-3793-7716
Jack PhuCentre for Eye Health, UNSW, Sydney, NSW, Australia.
Htein Linn AungNeuroscience Research Australia, Sydney, NSW, Australia.
Negin Hesam-ShariatiNeuroscience Research Australia, Sydney, NSW, Australia.
Lisa KeayThe George Institute for Global Health, Faculty of Medicine, UNSW, Sydney, NSW, Australia.
Phillip J TullySchool of Psychology, The University of New England, Armidale, NSW, Australia.
Andrew BoothSchool of Health and Related Research, University of Sheffield, Sheffield, UK.
Craig S AndersonThe George Institute for Global Health, Faculty of Medicine, UNSW, Sydney, NSW, Australia.
Kaarin J AnsteyNeuroscience Research Australia, Sydney, NSW, Australia.ORCID 0000-0002-9706-9316
Ruth PetersNeuroscience Research Australia, Sydney, NSW, Australia.
UNSW Sydney · AURoyal Prince Alfred Hospital · AUThe University of Sydney · AUUniversity of New England · AUUniversity of Sheffield · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveWe aim to quantify the co-existence of age-related macular degeneration (AMD), glaucoma, or diabetic retinopathy (DR) and cognitive impairment or dementia.

methodMEDLINE, EMBASE, PsycINFO and CINAHL were searched (to June 2020). Observational studies reporting incidence or prevalence of AMD, glaucoma, or DR in people with cognitive impairment or dementia, and of cognitive impairment or dementia among people with AMD, glaucoma, or DR were included.

resultsFifty-six studies (57 reports) were included but marked by heterogeneities in the diagnostic criteria or definitions of the diseases, study design, and case mix. Few studies reported on the incidence. Evidence was sparse but consistent in individuals with mild cognitive impairment where 7.7% glaucoma prevalence was observed. Prevalence of AMD and DR among people with cognitive impairment ranged from 3.9% to 9.4% and from 11.4% to 70.1%, respectively. Prevalence of AMD and glaucoma among people with dementia ranged from 1.4 to 53% and from 0.2% to 25.9%, respectively. Prevalence of DR among people with dementia was 11%. Prevalence of cognitive impairment in people with AMD, glaucoma, and DR ranged from 8.4% to 52.4%, 12.3% to 90.2%, and 3.9% to 77.8%, respectively, and prevalence of dementia in people with AMD, glaucoma and DR ranged from 9.9% to 62.6%, 2.5% to 3.3% and was 12.5%, respectively.

conclusionsFrequency of comorbid eye disease and cognitive impairment or dementia varied considerably. While more population-based estimations of the co-existence are needed, interdisciplinary collaboration might be helpful in the management of these conditions to meet healthcare needs of an ageing population.

trial registrationPROSPERO registration: CRD42020189484.

Indexed as

Cognitive DysfunctionDementiaDiabetic RetinopathyGlaucomaMacular DegenerationAgingHumans

Identifiers

PMID36922645
PMCPMC10564749
OpenAlexW4327679236

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.